Prognoza
Średnia cena docelowa analityków wynosi 45,17 € (+50,02%). Mediana wynosi 44,65 € (+48,29%).
| Kupuj |
8 |
| Trzymaj |
3 |
| Sprzedaj |
2 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Harmony Biosciences outlines second growth chapter with BP-205 and acquisition plans
Harmony is building on revenue driver WAKIX (on track for over $1 billion) and a broader pipeline approach. The company has about $963 million in cash, positions BP-205 as a leading orexin‑2 agonist and plans two to three business-development transactions expected to generate revenue in 2028–2032. In parallel, Harmony is defending WAKIX’s patent portfolio against generics and anticipates loss of exclusivity in March 2030. Several clinical milestones for BP-205 are targeted for late 2024 to mid-2026. » Więcej na de.investing.com
Harmony Biosciences reaches 52-week high after strong Wakix numbers
Harmony Biosciences shares rose to a new 52-week high of $42.70 and have a market capitalization of about $2.49 billion. In the second quarter, adjusted earnings per share of $1.28 beat expectations, and Wakix revenue hit a record $261.3 million, confirming the full-year guidance of $1.00–1.04 billion. Analysts remain positive (including outperform ratings with price targets of $60–70), despite ongoing IP disputes and competition from orexin agonists. InvestingPro sees the stock at a fair value of $59.06 and rates the financial condition as "EXCELLENT". » Więcej na de.investing.com
Harmony Biosciences presents strategy following WAKIX and expands CNS pipeline
Harmony outlines three strategic pillars: expanding the pitolisant franchise with Pitolisant GR (PDUFA April 27) and Pitolisant HD; advancing BP-205 as a potential best-in-class orexin-2 agonist; and developing EPX-100 for rare epilepsies. WAKIX delivered record quarterly sales and funds the pipeline growth, while key milestones are mostly expected in 2027/2028. BP-205 showed strong efficacy, rapid absorption and no relevant safety signals in early studies; EPX-100 demonstrated substantial seizure reductions in Dravet syndrome. The stock closed at $38.50 (-3.19%). » Więcej na de.investing.com
Harmony Biosciences posts strong Q1 results, keeps full-year revenue guidance above $1 billion
Harmony Biosciences reported Q1 2026 revenue of $215.4 million, a 17% year-over-year increase driven by continued adoption of WAKIX (pitolisant). Management reaffirmed full-year 2026 net revenue guidance of over $1 billion and highlighted strong operating leverage and cash generation funding its late-stage pipeline. The company is pursuing pediatric narcolepsy approval and exploring indications including idiopathic hypersomnia and Prader-Willi syndrome, supporting investor optimism about lifecycle and pipeline growth. » Więcej na finance.yahoo.com
Harmony Biosciences: WAKIX grows, heavy investments weigh on quarterly profit
Harmony reported Q1 2026 results: WAKIX revenue rose 17% to $215.4 million but missed consensus, and diluted earnings per share fell to $0.55, well below expectations. Management reaffirmed the full-year revenue guidance of $1.0–1.04 billion, attributing the earnings miss to high strategic investments, license costs and increased R&D spending. The company holds about $870.5 million in cash and highlights growth drivers such as enteric-coated and high‑dose pitolisant programs, a broad pipeline and legal actions to defend patents. Despite near-term profitability pressure, Harmony sees a clear path for WAKIX to reach the billion-dollar mark and plans to step up business development transactions. » Więcej na de.investing.com
Dane finansowe
W ostatnim kwartale HARMONY BIOSC.HLD.-,00001 osiągnęła przychody w wysokości 237,41 mln € i zysk netto w wysokości 42,55 mln €
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 237,41 mln | 16,35% |
| Zysk brutto | 166,18 mln | 8,46% |
| Zysk netto | 42,55 mln | 1,83% |
| EBITDA | 60,28 mln | 3,70% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 1,77 mld € |
Liczba akcji | 58,72 mln |
Maksimum/minimum z 52 tygodni | 39,63 € - 23,60 € |
| Dywidendy | Nie |
Beta | 0,98 |
C/Z (PE Ratio) | 10,75 |
PEG (PEG Ratio) | -2,18 |
C/WK (PB Ratio) | 1,80 |
C/S (PS Ratio) | 1,97 |
Profil spółki
Harmony Biosciences Holdings, Inc., firma farmaceutyczna będąca na etapie komercjalizacji, opracowuje i wprowadza na rynek terapie dla pacjentów z rzadkimi zaburzeniami neurologicznymi w Stanach Zjednoczonych. Jej produkt WAKIX to lek stosowany w leczeniu nadmiernej senności w ciągu dnia u dorosłych pacjentów z narkolepsją. Spółka wcześniej funkcjonowała jako Harmony Biosciences II, Inc. i zmieniła nazwę na Harmony Biosciences Holdings, Inc. w lutym 2020 roku. Harmony Biosciences Holdings, Inc. została założona w 2017 roku i ma siedzibę w Plymouth Meeting w stanie Pensylwania.
| Nazwa | HARMONY BIOSC.HLD.-,00001 |
| CEO | Jeffrey Dayno |
| Siedziba | Plymouth Meeting,
pa Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Materiały podstawowe |
| Branża | Chemikalia |
| Debiut giełdowy | 19.08.2020 |
| Pracownicy | 293 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | HRMY |